STAT

Opinion: I’m the ideal person to support right to try. But I can’t — it’s a disaster in the making

We don't need a new right-to-try law with iffy, or nonexistent, financial, legal and medical protection for patients. We already have one that works.
The FDA's expanded access program already offers people who are terminally ill access to experimental therapies.

During his first State of the Union address, President Trump urged Congress to aimed at giving terminally ill patients access to experimental drugs. As an individual with terminal cancer and a former biotechnology industry executive, I know that the “right to try” isn’t merely a theoretical concept. And while I can relate to patients’ desperate hopes and desires to try new therapeutic approaches, I believe that passage of the federal would be a disaster.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
STAT1 min read
STAT+: Oncologists Turn To Blood Test For Circulating Tumor DNA, But Questions Remain On How To Use The Data
A blood test known as a ctDNA test can be a good indicator of whether someone's cancer will return after surgery. But the test doesn't always clarify the next step…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Merck Pneumococcal Shot, Kansas Suing Pfizer, And More
In today's Pharmalittle roundup, we're reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more.

Related Books & Audiobooks